Knasmüller S, Schwab C E, Land S J, Wang C Y, Sanyal R, Kundi M, Parzefall W, Darroudi F
Institute of Cancer Research, University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
Mutagenesis. 1999 Nov;14(6):533-40. doi: 10.1093/mutage/14.6.533.
In order to study the mutagenic effects of heterocyclic aromatic amines (HAAs) in cells of human origin, five compounds, namely 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ), 2-amino-3, 4-dimethyl-imidazo[4,5-f]quinoline (MeIQ), 2-amino-3, 8-dimethyl-imidazo[4,5-f]quinoxaline (MeIQx), the pyridoimidazo derivative 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1), were tested in micronucleus (MN) assays with a human derived hepatoma (HepG2) cell line. All HAAs caused significant, dose-dependent effects. The activities of IQ, MeIQ, MeIQx and PhIP were similar (lowest effective concentrations 25-50 microM), whereas Trp-P-1 was effective at a dose of >/=2.1 microM. In addition, the HAAs were tested in MN assays with Chinese hamster ovary (CHO) cells and in Salmonella strain YG1024 using HepG2 cell homogenates as an activation mix. In the CHO experiments, positive results were obtained with Trp-P-1 and PhIP, whereas the other compounds were devoid of activity under all experimental conditions. The discrepancy in the responsivity of the two cell lines is probably due to differences in their acetylation capacity: enzyme measurements with 2-aminofluorene as a substrate revealed that the cytosolic acetyltransferase activity in the HepG2 cells is approximately 40-fold higher than that of the CHO cells. In the bacterial assays all five HAAs gave positive results but the ranking order was completely different from that seen in the HepG2/MN experiments (IQ > MeIQ > Trp-P-1 >/= MeIQx >> PhIP) and the mutagenic potencies of the various compounds varied over several orders of magnitude. The order obtained in bacterial tests with rat liver S9 mix was more or less identical to that seen in the tests with HepG2 cell homogenates but the concentrations of the amines required to give positive results were in general substantially lower (10(-5)-10(-1) microM). Overall, the results of the present study indicate that MN/HepG2 tests might reflect the mutagenic effects of HAAs more adequately than other in vitro mammalian cell systems due to the presence of enzymes involved in the metabolic conversion of the amines.
为了研究杂环芳香胺(HAAs)对人源细胞的致突变作用,选用了5种化合物,即2-氨基-3-甲基咪唑[4,5-f]喹啉(IQ)、2-氨基-3,4-二甲基咪唑[4,5-f]喹啉(MeIQ)、2-氨基-3,8-二甲基咪唑[4,5-f]喹喔啉(MeIQx)、吡啶并咪唑衍生物2-氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶(PhIP)和3-氨基-1,4-二甲基-5H-吡啶并[4,3-b]吲哚(Trp-P-1),采用人源肝癌(HepG2)细胞系进行微核(MN)试验。所有HAAs均产生了显著的剂量依赖性效应。IQ、MeIQ、MeIQx和PhIP的活性相似(最低有效浓度为25 - 50 microM),而Trp-P-1在剂量≥2.1 microM时有效。此外,使用HepG2细胞匀浆作为活化混合物,对HAAs进行了中国仓鼠卵巢(CHO)细胞微核试验以及沙门氏菌YG1024菌株试验。在CHO实验中,Trp-P-1和PhIP得到阳性结果,而其他化合物在所有实验条件下均无活性。两种细胞系反应性的差异可能是由于它们乙酰化能力的不同:以2-氨基芴为底物的酶活性测定表明,HepG2细胞中的胞质乙酰转移酶活性比CHO细胞高约40倍。在细菌试验中,所有5种HAAs均得到阳性结果,但排序与HepG2/MN实验中的结果完全不同(IQ > MeIQ > Trp-P-1 ≥ MeIQx >> PhIP),并且各种化合物的致突变能力相差几个数量级。用大鼠肝脏S9混合物进行细菌试验得到的排序与用HepG2细胞匀浆试验的结果大致相同,但产生阳性结果所需的胺类浓度通常要低得多(10^(-5) - 10^(-1) microM)。总体而言,本研究结果表明,由于存在参与胺类代谢转化的酶,MN/HepG2试验可能比其他体外哺乳动物细胞系统更能充分反映HAAs的致突变作用。